Characterization of tumor infiltrating Natural Killer cell subset

Oncotarget

Volumn 6, Issue 15, 2015, Pages 1-9

  Levi, Inbar ^a   Amsalem, Hagai ^a   Nissan, Aviram ^a   Darash Yahana, Merav ^a   Peretz, Tamar ^a   Mandelboim, Ofer ^b   Rachmilewitz, Jacob ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

Decidua; NK cells; TILs; VEGF

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CD9 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; INTERLEUKIN 2; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER TISSUE; CARCINOGENESIS; CELL SUBPOPULATION; COLON CANCER; CONTROLLED STUDY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PERITONEAL FLUID; PLEURA FLUID; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR INFILTRATING NATURAL KILLER CELL; BLOOD; CANCER STEM CELL; CASE CONTROL STUDY; FEMALE; HUMAN; IMMUNOLOGY; NEOPLASM; PREGNANCY;

CASE-CONTROL STUDIES; FEMALE; HUMANS; KILLER CELLS, NATURAL; NEOPLASMS; NEOPLASTIC STEM CELLS; PREGNANCY;

EID: 84931067367     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3453     Document Type: Article

References (17)

1. Trinchieri G. Biology of natural killer cells Advances in immunolog. 1989; 47:187-528.
2. Vgenopoulou S, Lazaris AC, Markopoulos C, Boltetsou E, Kyriakou V, Kavantzas N, Patsouris E, Davaris PS. Immunohistochemical evaluation of immune response in invasive ductal breast cancer of not-otherwise-specified type. Breast. 2003; 12:172-178.
3. Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED, Paul P. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol. 2002; 196:266-274.
4. Georgiannos SN, Renaut A, Goode AW, Sheaff M. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major his{reversed not sign}tocompatibility complex in cell-mediated immune mecha{reversed not sign}nisms, and their association with prognostic indicators. Surgery. 2003; 134:827-834.
5. Melichar B, Touskova M, Tosner J, Kopecky O. The phenotype of ascitic fluid lymphocytes in patients with ovarian carcinoma and other primaries. Onkologie. 2001; 24:156-160.
6. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, et al. Specific recruitment of regula{reversed not sign}tory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10:942-949.
7. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001; 22:633-640.
8. Koopman LA, Kopcow HD, Rybalov B, Boyson JE, Orange JS, Schatz F, Masch R, Lockwood CJ, Schachter AD, Park PJ, Strominger JL. Human decid{reversed not sign}ual natural killer cells are a unique NK cell subset with immunomodulatory potential. J Exp Med. 2003; 198:1201-1212.
9. Hanna J, Wald O, Goldman-Wohl D, Prus D, Markel G, Gazit R, Katz G, Haimov-Kochman R, Fujii N, Yagel S, Peled A, Mandelboim O. CXCL12 expression by invasive trophoblasts induces the specific migration of CD16- human natural killer cells. Blood. 2003; 102:1569-1577.
10. Okamoto N, Uchida A, Takakura K, Kariya Y, Kanzaki H, Riittinen L, Koistinen R, Seppala M, Mori T. Suppression by human placental protein 14 of natural killer cell activity. Am J Reprod Immunol. 1991; 26:137-142.
11. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I, Gazit R, Yutkin V, Benharroch D, Porgador A, Keshet E, Yagel S, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. 2006; 12:1065-1074.
12. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331:44-49.
13. Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, Ferlazzo G. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer. 2008; 112:863-875.
14. Bai XX, Kong BH, Zhang YZ, Qu X, Wang HL. Expression and significance of chemokine CXC receptor 3, 4 and their ligands at the early pregnancy decidua and villi. Zhonghua Fu Chan Ke Za Zhi. 2008; 43:904-908.
15. Pokkali S, Das SD, Selvaraj A. Differential upregula{reversed not sign}tion of chemokine receptors on CD56 NK cells and their transmigration to the site of infection in tubercu{reversed not sign}lous pleurisy. FEMS Immunol Med Microbiol. 2009; 55:352-360.
16. DeLong P, Carroll RG, Henry AC, Tanaka T, Ahmad S, Leibowitz MS, Sterman DH, June CH, Albelda SM, Vonderheide RH. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther. 2005; 4:342-346.
17. Bamias A, Tsiatas ML, Kafantari E, Liakou C, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, Tsitsilonis O, Bamia C, Papatheodoridis G, Politi E, Archimandritis A, Antsaklis A, Dimopoulos MA. Significant differences of lymphocytes isolated from ascites of patients with ovar{reversed not sign}ian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Gynecol Oncol. 2007; 106:75-81.